Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib.
Thomas GaillardJeanne PikettyJean-Guillaume FeronNoemie GirardLea PaulyElodie GauroyLauren DarriguesBeatriz GrandalJean-Yves PiergaAnne-Sophie Hamy-PetitFabien ReyalEnora LaasPublished in: British journal of cancer (2024)
The MonarchE trial may significantly affect surgical practices due to the need for invasive procedures to identify high-risk patients for adjuvant abemaciclib treatment. The prospect of unnecessary morbidity demands less invasive N2 status determination methods. Surgical decisions must consider patient health and potential treatment benefits.
Keyphrases
- healthcare
- end stage renal disease
- clinical trial
- study protocol
- primary care
- public health
- newly diagnosed
- lymph node
- early stage
- chronic kidney disease
- phase iii
- peritoneal dialysis
- phase ii
- mental health
- case report
- radiation therapy
- health information
- human health
- climate change
- risk assessment
- neoadjuvant chemotherapy
- sentinel lymph node
- patient reported outcomes
- open label
- solid phase extraction
- patient reported
- molecularly imprinted